Erythropoietin markedly attenuates brain infarct size and improves neurological function in the rat

Journal of Investigative Medicine

Volumn 58, Issue 7, 2010, Pages 893-904

  Chun Man, Yuen ^a   Steve, Leu ^b   Fan Yen, Lee ^c   Chia Hung, Yen ^d   Yu Chun, Lin ^b   Sarah, Chua ^b   Sheng Ying, Chung ^b   Han Tan, Chai ^b   Jiunn Jye, Sheu ^c   Sheung Fat, Ko ^e   Cheuk Kwan, Sun ^f,g   Hon Kan, Yip ^b  

^a Division of Neurosurgery   (Taiwan)

^b Division of Cardiology   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e Department of Radiology ^*  (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acute ischemic stroke; EPO treatment

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; DOUBLECORTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 18; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; VON WILLEBRAND FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN FUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; INTERNAL CAROTID ARTERY OCCLUSION; MALE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ADULT; BONE MARROW DERIVED MONONUCLEAR CELL; CELL NUCLEUS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; TUNEL ASSAY;

RATTUS;

EID: 85008256418     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/jim.0b013e3181e80c40     Document Type: Article

References (38)

1. American Heart Association. Stroke Statistics. Dallas, TX: American Heart Association; 2002.
2. Hankey GJ. Stroke: how large a public health problem, and how can the neurologist help? Arch Neurol. 1999;56:748-754.
3. World Health Organization. World Health Report 1999-Making a Difference. Geneva, Switzerland: World Health Organization; 1999.
4. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
5. Chen Z, Sandercock P, Pan H, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000;31:1240-1249.
6. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559-2566.
7. Muir KW, Weir CJ, Murray GD, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817-1820.
8. Yip HK, Liou CW, Chang HW, et al. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis. 2005;20:120-128.
9. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
10. Wardlaw JM, del Zoppo GJ, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009; (3): CD000213.
11. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115: e478-e534.
12. Bravata DM. Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice. CNS Drugs. 2005;19:295-302.
13. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35:1490-1497.
14. Thomalla G, Sobesky J, Kohrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38:313-318.
15. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci. 2003;100:4802-4806.
16. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48:176-184.
17. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci. 2003;100:11612-11617.
18. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990-994.
19. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci. 2000;97:10526-10531.
20. Lin JS, Chen YS, Chiang HS, et al. Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization. J Physiol. 2008;586:5757-5769.
21. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
22. van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J. 2004;25:285-291.
23. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198:971-975.
24. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-647.
25. Kawakami M, Sekiguchi M, Sato K, et al. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem. 2001;276:39469-39475.
26. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732-1737.
27. Hua Y, Schallert T, Keep RF, et al. Behavioral tests after intracerebral hemorrhage in rat. Stroke. 2002;33:2478-2484.
28. Ozawa T, Toba K, Kato K, et al. Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol. 2006;40:629-638.
29. Bowie MB, McKnight KD, Kent DG, et al. Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest. 2006;116:2808-2816.
30. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879-894.
31. Wei YJ, Tang Y, Li J, et al. Cloning and expression pattern of dog SDF-1 and the implications of altered expression of SDF-1 in ischemic myocardium. Cytokine. 2007;40:52-59.
32. Kahn J, Byk T, Jansson-Sjostrand L, et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood. 2004;103:2942-2949.
33. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322-1328.
34. Zhang D, Fan GC, Zhou X, et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol. 2008;44:281-292.
35. Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300-3305.
36. Hu X, Dai S, Wu WJ, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation. 2007;116:654-663.
37. Sun CK, Chang LT, Sheu JJ, et al. Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009;37:1197-1205.
38. Yip H-K, Chang L-T, Wu C-J, et al. Autologous bone marrow-derived mononuclear cell therapy prevents the damage of viable myocardium and improves rat heart function following acute anterior myocardial infarction. Circulation J. 2008;72:1336-1345.